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Abstract
Objective: In the United Kingdom and other European Union countries guidelines for driving following a first unprovoked
seizure require the risk of another seizure in the next year to be less than 20%. Using data from one clinical trial, we
previously developed a prognostic model to inform driving guidelines. The objective of this work is to externally validate
our published model and demonstrate its generalisability.
Methods: A cohort of 620 people with a first unprovoked seizure was used to develop the original model which included
variables for aetiology, first degree relative with epilepsy, seizures only while asleep, electroencephalogram, computed
tomography or magnetic resonance scan result, and treatment policy. The validation cohorts consisted of 274 (United
Kingdom), 305 (Italy), and 847 (Australia) people. The model was evaluated using discrimination and calibration methods. A
covariate, missing from the Italian dataset, was handled via five imputation methods. Following external validation, the
model was fitted to a pooled population comprising all validation datasets and the development dataset. The model was
stratified by dataset.
Results: The model generalised relatively well. All methods of imputation performed fairly similarly. At six months, the risk of
a seizure recurrence following a first ever seizure, based on the pooled datasets, is 15% (95% CI: (12% to 18%)) for patients
who are treated immediately and 18% (95% CI: (15 to 21%)) otherwise. Individuals can be reliably stratified into risk groups
according to the clinical factors included in the model.
Significance: Our prognostic model, used to inform driving regulations, has been validated and consequently has been
proven as a valuable tool for predicting risk of seizure recurrence following a first seizure in people with various
combinations of risk factors. Additionally, there is evidence to support one worldwide overall prognostic model for risk of
second seizure following a first.
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Introduction
In the UK and other EU countries, following a first unprovoked
seizure, the majority of people are allowed to return to driving a
car (group 1 license holders) once they have gone six months
without a seizure - by this time point their risk of a subsequent
seizure in the next 12 months is estimated to have dropped below
20%. This recommendation is in part informed by prognostic
modelling of data from the Multicentre Study of Early Epilepsy
and Single Seizures (MESS) [1,2]. A prognostic model was also
developed [3] aiming to determine the overall population risk of a
seizure recurrence in the next 12 months at differing time points
after a first seizure, and to identify which clinical factors influenced
seizure recurrence risk. This allowed people with a first seizure to
be stratified according to the risk of seizure recurrence, including
those with a 12 month recurrence risk below 20% and those with a
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risk above 20% six months after a first seizure. The model
included variables for aetiology, epilepsy in a first degree relative,
seizure while asleep, electroencephalogram (EEG) results, com-
puted tomography or magnetic resonance (CT/MRI) imaging
scan results, and treatment policy [3].
Before a predictive or prognostic model can be introduced into
routine practice, it should be externally validated to ensure it
performs satisfactorily in datasets that are fully independent of the
development data [4]. The datasets used to externally validate the
model should be plausibly related to the development data
meaning that all datasets will effectively be samples taken from the
same super-population [4]. In the case of MESS there are several
plausibly related datasets for which we have individual patient
data: (1) The UK-based National General Practice Study of
Epilepsy (NGPSE) [5], (2) data prospectively collected at hospital-
based epilepsy clinics in Perth, Western Australia (WA) [6,7], and
(3) the FIRST (FIRST) dataset from Italy [8–10].
We describe the external validation of the model from MESS in
these external datasets. External validation of our prognostic
model demonstrated that it is a valuable tool for predicting risk of
seizure recurrence following a first seizure in people with various
combinations of risk factors. Additionally, we fit the prognostic
model to a combined dataset of MESS, NGPSE, WA and FIRST.
A good model fit to the dataset provided support for one
worldwide overall prognostic model for risk of second seizure
following a first which will enable driving regulations worldwide to
be harmonised.
Methods
Description of Studies
The data for each study used in these analyses are available
from representatives of the original studies – these are listed as co-
authors.
Study used for model development. MESS [1] was a UK-
based randomised controlled trial that compared the policies of
immediate or deferred treatment in people presenting with a first
unprovoked seizure, or with epilepsy, where both the clinician and
patient were uncertain about the need for antiepileptic drug (AED)
treatment. MESS remains the largest reported study of people
with single seizures and early epilepsy, and while the primary
purpose of the study was to compare treatment policies, it also
provided an important opportunity to examine seizure recurrence
risks and factors that modify those risks.
Studies used for validation. The NGPSE [5] was initiated
in 1984 and used the UK primary care system to obtain
comprehensive data on a large and unselected cohort of people
with newly diagnosed seizures, including children with febrile
seizures. Patients were ascertained for the study via their general
practitioner (GP), but were never contacted directly by the study
team. Accepted practice at the time for observational studies, was
that individuals did not need to be asked for consent as their care
was never affected by inclusion in such studies. Over a thousand
people were initially referred by their GPs, of who a quarter were
children with febrile seizures. About two thirds had definite or
probable epilepsy and seizure dates were ascertained retrospec-
tively in a proportion.
The WA [6,7] dataset included adults referred to the First
Seizure Clinics of Royal Perth and Fremantle Hospitals, two
major teaching hospitals in Western Australia. Recruitment began
in January 1999 and is on-going. The data presented here
represent information collected up until March 2011.
The FIRST [8–10] dataset comprises participants from a
randomised clinical trial that compared immediate and deferred
antiepileptic drug treatment after a first unprovoked tonic-clonic
seizure. Starting on February 1, 1988, all patients examined in 14
university clinics and hospitals in Italy with a first previously
untreated, unprovoked tonic-clonic seizure were considered for
recruitment. Some FIRST participants were followed up for ten
years although the data described here includes only six years of
follow-up.
Table 1 provides a demographic summary of people in MESS,
NGPSE, FIRST and WA. Patients with missing outcome data (no
data following index seizure) have been excluded – for this reason
Table 1 summarises 620 patients within the MESS dataset rather
than the 637 summarised in the earlier publication [3].
In all of the included studies, when treatment was given, the
clinician chose the drug they considered optimum for the
individual. In MESS, people who were randomised to treatment
were given carbamazepine (46%), valproate (46%), phenytoin
(3%), lamotrigine (3%), or another drug (2%). In NGPSE, many
AEDs were prescribed but the most common were phenytoin
(37% of all treated participants), carbamazepine (36%), and
sodium valproate (19%). In WA, initial AED selection included
valproate (36%), phenytoin (47%), and carbamazepine (12%). In
FIRST, of those who were treated, the most common AEDs
prescribed were phenobarbital (50%), carbamazepine (30%),
sodium valproate (16%), and phenytoin (5%).
External Validation
A review of studies [11] that externally validated a prognostic
model over the last ten years found that the most frequently
implemented methods of external validation were discrimination
(64 of 109 studies) and calibration (23 of 109 studies) and we
employed these methods. (Full details of the literature review are
available on request). We examined discrimination via Harrell’s c-
index [12] and calibration via calibration plots [13]. We also
considered discrimination and calibration via Kaplan-Meier
curves and hazard ratios for risk groups [14].
Discrimination is the ability of a model to allocate people who
experience the event of interest a higher predicted probability of
experiencing the event than that allocated to those who did not
experience the event. We assessed discrimination via Harrell’s c-
index [12]. This measures the proportion of all possible patient
pairs – all possible combinations of patients where one patient has
the event and the other does not, and the patient with the event
has the shorter follow-up time - in which the predictions and
outcomes are concordant. If the predicted time free of the event is
longer for the subject who did not experience the event, the
predictions for that pair are concordant with the outcomes. A
value of c of 0.5 corresponds to the concordance expected by
chance and 1 corresponds to perfect concordance. For example, a
c-statistic of 0.6 would mean that, for a random pair of patients,
the probability of the patient who had a second seizure first having
the shorter predicted probability of a second seizure is 60%. It is
calculated using the ‘coxph’ package with R.
Kaplan-Meier curves for risk groups can be used in assessing
both model discrimination and calibration. The more widely
separated the curves, the better the discrimination. Discrimination
can also be compared between datasets by visually comparing the
Kaplan-Meier curves for the risk groups. Additionally, if two
survival curves are more widely separated the hazard ratios for the
groups tend to be larger.
Calibration describes how well the estimates of risk from the
model correspond to the risk from the observed data [13] and can
be described as a measure of the extent of bias in a model. A
model is well calibrated when predicted and observed probabilities
of an event agree. We assessed calibration by plotting the observed
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probabilities of a second seizure against predicted probabilities of
the event based on the fitted model. If the model was perfectly
calibrated, the predicted and observed values would rest on a 45
degree line – the predicted probability of a second seizure for a
patient would be identical to their observed probability of a second
seizure [14]. The plots were created using the ‘val.surv’ function
within R. Good calibration may also be inferred if the survival
curves for a given risk group agree well between the development
and validation datasets [14].
Data Analysis
In the original MESS model and the work presented here, we
included people aged 16 years or over on the day of their first
seizure as this population are most relevant to driving. The
outcome, time from first to second seizure, was calculated for each
individual with observations censored at date of last follow-up if a
second seizure was not experienced.
Model discrimination and calibration were examined for the
Cox proportional hazards model fitted to the MESS data and also
for the equivalent model fitted to the validation datasets in turn.
The difference in the concordance between the development and
validation dataset was then calculated. If the differences were
similar (informally assessed; #0.05) it was reasonable to conclude
that the model was externally valid. Additionally, we created risk
groups for MESS by categorising the prognostic index into four
groups using cut-points on the prognostic index determined by
Cox’s method which minimises the loss of information that occurs
with grouping [15]. The required cut-points are the 16th, 50th and
84th centiles, giving two smaller groups at relatively low and high
risk of recurrence and two larger groups at lower and higher
intermediate risks [14]. These risk groups were fitted to each
dataset (MESS, NGPSE, WA and each type of imputed FIRST
dataset), plotted, and associated hazard ratios were calculated. We
also produced a Kaplan-Meier curve for the low risk group in each
Table 1. Demographics of all analysed participants: bold entries relate to variables included in the MESS multivariable model.
MESS NGPSE WA FIRST
Characteristic (n = 620) (n =274) (n=847) (n=305)
Age at first
seizure in years
Median
(IQR)
33?0 (21?9, 49?9) 50?3 (31?8, 68?8) 39?0 (26?0, 56?0) 28?0 (20?0, 46?0)
Gender
Male 404 (65) 135 (49) 540 (64) 173 (57)
Aetiology
Remote
symptomatic
99 (16) 156 (57) 270 (32) 22 (7)
Epilepsy in first
degree relative
Yes 67 (11) 21 (8) 93 (11) 36 (12)
No 553 (89) 253 (92) 730 (86) 269 (88)
Missing - - 24 (3) -
First seizure
occurred from
sleep
Yes 109 (18) 40 (15) 202 (24) NA
No 510 (82) 234 (85) 643 (76) NA
Missing 1 (0) - 2 (0) NA
EEG results
Normal 278 (45) 50 (18) 420 (50) 144 (47)
Abnormal 304 (49) 71 (26) 405 (48) 161 (53)
Not clinically
indicated
38 (6) 153 (56) 22 (2) -
CT/MRI scan results
Normal 444 (72) 57 (21) 541 (64) 246 (81)
Abnormal 72 (11) 39 (14) 240 (28) 59 (19)
Not clinically
indicated
104 (17) 178 (65) 66 (8) -
Treatment Policy
Immediate/On
Treatment
307 (50) 78 (28) 233 (28) 156 (51)
Entries are number (%) unless otherwise stated.
NA=Not available.
doi:10.1371/journal.pone.0099063.t001
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dataset and visually determined calibration by comparing the
curves for NGPSE, WA and FIRST to the curve for MESS.
‘Seizures only while asleep’ was missing completely from
FIRST. Therefore five methods of handling a missing covariate
were applied when assessing external validation via the FIRST
dataset: (1) variable matching – refit the model with the
development dataset restricted to include only covariates that
are available in the validation dataset; (2) random selection with
replacement – each entry of the missing variable is imputed by
randomly selecting an entry from the equivalent variable in the
development dataset; (3) single imputation via estimated propor-
tions – each entry of the missing variable is imputed with a
random number based on the summary statistic(s) of the
equivalent variable in the development dataset; (4) hot deck
imputation – each entry of the missing variable is imputed with
values recorded for similar respondents in the development data;
and (5) random selection with replacement multiple times – values
of the missing covariate from the development set are randomly
selected, with replacement, to produce a number of datasets which
are averaged to produce an imputed covariate.
Handling missing data in these ways may lead to biased
estimates or data that do not reflect the sampling variability and
marginal distributions which could lead to distorted associations
[16]. However, simply ignoring the missing variable would be
Figure 1. Kaplan-Meier curve for time from first to second seizure for MESS, NGPSE, WA and FIRST with numbers at risk.
doi:10.1371/journal.pone.0099063.g001
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more problematic as it would prevent inclusion of FIRST for
model validation.
Covariate values missing for some participants were excluded
from these analyses. In FIRST, unlike the other studies, all
participants had an EEG and CT/MRI hence there was no ‘not
clinically indicated’ category. Following a sensitivity analysis, the
EEG and CT/MRI variables were collapsed to two categories
each in MESS (normal or abnormal) to match FIRST for the
external validation of MESS via FIRST only.
Fitting of Model to Super-population
Having shown that the model developed using the MESS data
generalised fairly well to the NGPSE, WA and FIRST datasets, we
fitted the MESS prognostic model to a combined dataset (super-
population) of all four datasets to further improve generalisability
and precision. The model was stratified by study and the missing
sleep variable in FIRST was treated as missing data within the
sleep covariate for this super-population model.
Given the issue with the ‘sleep’ variable in FIRST we also
performed a sensitivity analysis which excluded FIRST from the
pooled analysis. Additionally we performed a sensitivity analysis
Figure 2. Calibration plots for MESS compared to NGPSE (A), WA (B), FIRST - variable matching (C) and FIRST - hot deck imputation
(D).
doi:10.1371/journal.pone.0099063.g002
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which excluded WA from the pooled analysis as it showed the
poorest validation of the MESS model.
The probability of someone who is seizure free at six months
after the index seizure, remaining seizure free throughout months
seven to 18 was calculated by dividing the probability of being
seizure free for 18 months by the probability of being seizure free
for six months. This can be interpreted as the relative probability
of being seizure free to 18 months if six months seizure freedom
has already been achieved. Conditional probabilities for other time
points were calculated similarly, and the confidence intervals for
these estimates were calculated utilising a revised version of
Greenwood’s formula [17–19].
To determine annual recurrence risks for combinations of risk
factors the baseline survivor function was estimated from the
multivariable model assuming a piecewise linear assumption. The
estimate was subsequently raised to a suitable power calculated
from combinations of variable coefficient estimates [20]. From
this, conditional probabilities can be calculated in the manner
described above.
Additionally, the seizure recurrence risk in the next 12 months
for any combination of risk factors can be calculated for each time
point. Consequently the time point where the seizure recurrence
risk in the next 12 months falls below 20% can be determined –
the risk threshold for returning to drive.
Results
As might be expected, there are some differences in participant
characteristics across the datasets. People in NGPSE tended to be
older than those in MESS and there were more females in
NGPSE, although the variables for age and gender were not
included in the multivariable model validated. Considerably more
people in NGPSE were classified as having a remote symptomatic
aetiology than those in MESS while FIRST had a lower rate
suggesting that there may be systematic differences in the way this
was classified across studies. In the NGPSE cohort there were
more results for EEG and CT/MRI scan that were not clinically
indicated, in part reflecting the era in which the study was
undertaken. Characteristics for people in the WA dataset were
mostly similar to those in MESS. The Kaplan-Meier curve for
these datasets, Figure 1, shows WA also had a higher risk of
seizure.
The FIRST dataset had a similar distribution of characteristics
to those of MESS. Patients in FIRST, that were available for this
analysis, were followed-up for a considerably shorter duration than
those in MESS.
Despite the differences in characteristics and follow-up it is
plausible that the NGPSE, FIRST and WA datasets came from
the same ‘super-population’ as MESS. This is because all four
datasets consider patients with a first unprovoked seizure and
consequently can be considered to come from the same super-
population of patients.
FIRST is the closest match to MESS in terms of the proportions
of patients with certain characteristics, however, the follow-up is
shorter and a covariate that was significant in the model is missing
(seizures while asleep). In the case of NGPSE and WA,
information on the same number of covariates is available but
the proportions of patients with some characteristics are not always
similar to the MESS data, in particular, the proportion of people
with remote symptomatic aetiology in NGPSE. However, this
again represented clinical practice where, in many cases, the only
similarity between patients is that they have had a seizure.
External Validation Results
Figure 2 shows calibration plots for external validation of MESS
with NGPSE (Figure 2A), WA (Figure 2B) and FIRST (Figure 2C
& 2D). Only plots for variable matching (Figure 2C) and hot deck
imputation (Figure 2D) methods are shown for FIRST but plots
for the other three methods of handling a missing covariate are
similar. NGPSE appears to validate quite well while the WA
dataset displays the poorest external validation. The FIRST data
displays the best calibration plot – the data fits very well along the
45 degree line. This may be because of the imputation which
makes the dataset artificially related to MESS. Therefore, in a
sensitivity analysis, we also fitted calibration plots with the model
that excludes the sleep variable. The plots were very similar to
those shown in Figure 2 (not shown here but available on request).
Concordance estimates and confidence intervals (Table 2) for
NGPSE and WA are very similar to those of MESS, suggesting
that the MESS model generalises well. Confidence intervals for the
concordance statistics using the FIRST data are fairly similar
Table 2. Summary of discrimination measure for MESS, NGPSE, WA and FIRST.
Dataset and
modifications
Concordance (c)
statistic (95%
Confidence Interval)
Difference in
Concordance
statistic
MESS 0?59 (0?56, 0?63) NA
NGPSE 0?60 (0?55, 0?65) 0?01
WA 0?59 (0?56, 0?62) 0?00
MESS: No Sleep Variable* 0?58 (0?54, 0?61) NA
FIRST: Variable Matching 0?65 (0?59, 0?70) 0?07
MESS: Sleep Variable** 0?59 (0?55, 0?62) NA
FIRST: Random Selection 0?65 (0?60, 0?70) 0?06
FIRST: Single Imputation 0?65 (0?60, 0?71) 0?06
FIRST: Hot Deck 0?66 (0?60, 0?71) 0?07
FIRST: Multiple Imputation 0?65 (0?60, 0?70) 0?06
*Sleep variable removed to match variables available in the FIRST dataset; EEG & CT/MRI scan result reduced to two categories.
**Sleep variable re-included; EEG & CT/MRI result reduced to two categories.
NA=Not applicable.
doi:10.1371/journal.pone.0099063.t002
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across all imputation methods. It is likely that the c-index for the
FIRST dataset is higher than in the original MESS study due to
the case mix – FIRST is a more homogenous population as it
includes patients with only a first tonic-clonic seizure while MESS
also included patients with other seizure types [21]. Together with
the relatively small differences in concordance between MESS and
the imputed FIRST datasets, the MESS model seems to generalise
fairly well to the FIRST data too.
The Kaplan-Meier curve for the MESS risk groups can be seen
in Figure 3 (Figure 3A). Kaplan-Meier curves for the fitting of
these risk groups to NGPSE (Figure 3B), WA (Figure 3C) and
FIRST (Figure 3D) can also be seen. Only the results for the hot-
deck imputation of the sleep variable in FIRST are shown, but
plots of the other four imputation methods are similar. MESS,
NGPSE and FIRST display well separated curves suggesting good
discrimination. WA on the other hand displays poor separation
and consequently poor discrimination.
The hazard ratios for the risk groups can be seen in Table 3.
The results for NGPSE and FIRST are similar to the MESS
results, irrespective of the imputation method used for the FIRST
dataset. This confirms our conclusion of good model discrimina-
tion. The hazard ratios for WA are not very comparable which
suggests poor discrimination.
Figure 3. Kaplan-Meier curves for risk groups in MESS (A) fitted to NGPSE (B), WA (C) and FIRST – hot deck imputation (D).
doi:10.1371/journal.pone.0099063.g003
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As shown in Figure 4, survival curves for the low risk group
agree well between MESS (development dataset) and NGPSE as
well as between MESS and FIRST – only hot deck imputation
results are shown here but results for the other methods of
imputation are very similar. This infers good calibration in these
cases. The agreement is not so good for WA confirming our
calibration plot which showed poor calibration for WA. Addi-
tionally, from these plots, we can see that low risk patients have a
less than 20% risk of a second seizure for about two years after
their index seizure.
Refitting of Model to ‘Super-population’
Having shown that the model developed using the MESS data
generalises fairly well, we proceeded to fit the model in a combined
dataset (super-population) of MESS, NGPSE, WA and FIRST,
stratified by study, to improve generalisability and precision.
Effect estimates from the multivariable models fitted in the two
sensitivity analyses can be seen in Table S1. The first sensitivity
analysis excluded FIRST from the pooled analysis because of the
missing ‘sleep’ variable in FIRST. The second excluded WA as it
showed the poorest validation of MESS. The results were broadly
similar to those for the pooled analysis including all four datasets.
Effect estimates from the multivariable model from both MESS
and the super-model can be seen in Table 4. The estimates are
very similar to those from the MESS model and, as expected, the
confidence intervals are narrower due to the additional data
included.
Table 5 shows the risk of seizure recurrence over 12 months for
a range of periods of seizure freedom following a first seizure,
estimated from the super-population model. The risk of a seizure
in the next 12 months is significantly below the 20% risk threshold
set by the Driving and Vehicle Licensing Agency (DVLA) after six
months for people who were treated immediately. The point
estimate for people who did not start treatment is below 20% but
the upper bound of the confidence interval is 21%.
Figure 5 shows the risk of seizure recurrence in the next 12
months for differing groups estimated from the super-population
multivariable model. These estimates are conditional on the
individual being recurrence free at six and 12 months following a
first seizure. These results assume seizures are not confined to sleep
and that there are no first degree relatives with epilepsy. The figure
also shows (in blue) the time point at which the estimate for seizure
recurrence drops below 20%.
Of note are the results for people with an idiopathic or
cryptogenic seizure with a normal CT/MRI and an abnormal
EEG who do not start AED treatment; at six months following a
first seizure this group has a recurrence risk significantly above
20%, although the estimate falls below 20% at 7.4 months.
Similarly, for those with a remote symptomatic seizure and an
abnormal EEG but normal CT/MRI, the recurrence risk does not
drop below 20% until 9.2 months if AED treatment is started and
11.7 months if it is not. An abnormal CT/MRI has a smaller
impact than EEG on recurrence risk. At six months after a first
seizure the 12 month recurrence risk estimates are below 20% for
people with a cryptogenic/idiopathic seizure, an abnormal CT/
MRI, and a normal EEG whether they start AED treatment or
not.
Discussion
We have investigated the external validity of a prognostic model
for risk of a second seizure following a first ever seizure via the
NGPSE, WA and FIRST datasets. Following fair external
validation of the MESS model using NGPSE, WA and FIRST,
we fitted the MESS model to a super-population comprising all
four datasets. These data can further inform driving regulations
and the current DVLA guidelines [22] that state, following a first
unprovoked seizure, a person must refrain from driving for six
months unless there are clinical factors or investigation results
which suggest an unacceptably high risk of a further seizure, i.e.
20% or greater per annum, in which case the time off driving is
increased.
Model Validation
The MESS model appears to be externally valid, to different
degrees, using different datasets although with respect to individual
studies, the discrimination and calibration measures appear to give
rather discrepant conclusions. The model generalises fairly well to
Table 3. Hazard ratios for risk groups in MESS fitted to NGPSE, WA and FIRST.
Risk Group Comparison
Hazard Ratio (95% Confidence Interval)
Dataset
Moderately Low
vs. Low
Moderately High
vs. Low High vs. Low
MESS 1?54 (0?95, 2?52) 2?12 (1?31, 3?42) 3?11 (1?86, 5?22)
NGPSE 1?48 (0?77, 2?89) 1?67 (0?89, 3?14) 2?82 (1?41, 5?63)
WA 2?11 (1?58, 2?82) 2?34 (1?83, 3?00) 2?46 (1?72, 3?52)
MESS: No Sleep Variable* 1?62 (1?09, 2?40) 2?02 (1?40, 2?93) 3?00 (2?02, 4?44)
FIRST: Variable Matching 1?50 (0?71, 3?17) 1?84 (1?06, 3?18) 2?71 (1?68, 4?36)
MESS: Sleep variable** 1?54 (0?95, 2?52) 2?12 (1?31, 3?42) 3?11 (1?86, 5?22)
FIRST: Random Selection 1?35 (0?71, 2?58) 1?94 (1?05, 3?60) 3?06 (1?73, 5?41)
FIRST: Single Imputation 1?62 (0?82, 3?20) 2?33 (1?20, 4?54) 3?78 (2?02, 7?07)
FIRST: Hot Deck 1?74 (0?89, 3?41) 2?10 (1?06, 4?15) 3?85 (2?06, 7?19)
FIRST: Multiple Imputation 1?74 (0?89, 3?41) 2?18 (1?11, 4?29) 3?77 (2?02, 7?06)
*Sleep variable removed to match variables available in the FIRST dataset; EEG & CT/MRI scan result reduced to two categories.
**Sleep variable re-included; EEG & CT/MRI result reduced to two categories.
NA=Not applicable.
doi:10.1371/journal.pone.0099063.t003
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the NGPSE and WA datasets and not quite so well to the FIRST
dataset according to the c-statistic while it generalises very well to
FIRST, quite well to NGPSE and poorly to WA according to the
calibration plots. According to the Kaplan-Meier curves for the
risk groups and the associated hazard ratios, the model generalised
fairly well to NGPSE and FIRST but poorly to WA, conclusions
also reached by visual inspection of the curves for low risk patients.
The differences in discrimination could be because of the
heterogeneity in EEG and CT/MRI scan results – results were
classified differently in FIRST than in MESS which may explain
why the model discrimination was poorer for FIRST according to
the c-statistic. The differences in calibration may be because of the
varying risks of seizure recurrence across the studies – patients in
WA tended to have a higher risk of a seizure recurrence than those
in MESS and patients in NGPSE also showed a slightly higher risk
of seizure recurrence in the four years after recruitment than
MESS.
Clinical Messages
The combined studies have over 2,000 people, more than three
times the number in MESS. Therefore the estimates derived from
the model are more accurate with smaller confidence intervals.
These results based on a super-population of people with a first
unprovoked seizure, provide further evidence that, in general, the
risk of seizure recurrence following a first ever seizure falls below
20% by six months irrespective of the treatment policy. Subgroups
at higher risk can, however, be identified. If a decision is made not
to start AED treatment, all those with a remote symptomatic
seizure have a significantly greater than 20% recurrence risk at six
months following a first seizure, while if treatment is started those
with a remote symptomatic seizure and a normal EEG do not. If a
decision is made not to start treatment for people with a
cryptogenic/idiopathic seizure, those with an abnormal EEG
have a significantly greater than 20% recurrence risk at six months
following a first seizure, while if treatment is started they do not.
Driving regulators will need to take these results into account
when deciding driving policy and in particular whether to attempt
to stratify risk in their guidance. The decisions made by regulators
Figure 4. Kaplan-Meier curve for low risk patients in MESS, NGPSE, WA and FIRST – hot deck imputation.
doi:10.1371/journal.pone.0099063.g004
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could influence decisions about starting treatment, especially for
higher risk groups who might be able to return to driving sooner if
they started antiepileptic drug treatment. Clinicians will need to
take account of these results when deciding which investigations
are required and when counselling patients about starting
treatment. The prognostic importance of an abnormal EEG
may be challenging, as patients who have this finding may be
disadvantaged compared to patients that do not have an EEG.
One could argue that this should be communicated with patients
before an EEG is requested.
Limitations
The study has certain methodological limitations. Firstly, we
have not fitted interaction terms in the multivariable model.
Additionally, only four of several possible methods of external
validation have been considered and the methods do not lead to
the same conclusions. In addition, rather than a clear-cut answer,
different degrees of external validation are likely and the degree of
‘acceptable’ external validity may be influenced by what the model
will be used for as the consequences of a poorly validated model in
practice may have very different impacts.
Data used to externally validate a prognostic model should
come from the same super-population. There are, however, no
guidelines suggesting how to check whether the development and
Table 4. Effect estimates from the multivariable model – MESS multivariable model fitted to super-population comprising MESS,
NGPSE, WA and FIRST.
Hazard Ratio (95% CI)
Covariate MESS Super-population
Cause of seizure
Not remote symptomatic 1.00 1.00
Remote symptomatic 1.33 (0.95, 1.87) 1.36 (1.15, 1.62)*
Epilepsy in first degree relative
No 1.00 1.00
Yes 1.33 (0.94, 1.90) 1.32 (1.09, 1.60)*
Seizures only while asleep
No 1.00 1.00
Yes 1.47 (1.09, 1.97)* 1.31 (1.12, 1.53)*
EEG results
Normal 1.00 1.00
Abnormal 1.55 (1.20, 2.01)* 1.48 (1.29, 1.71)*
Not clinically indicated 1.29 (0.74, 2.27) 1.12 (0.83, 1.51)
CT or MRI scan results
Normal 1.00 1.00
Abnormal 1.07 (0.72, 1.61) 1.08 (0.89, 1.29)
Not clinically indicated 1.29 (0.94, 1.78) 1.00 (0.81, 1.23)
Treatment policy
Delayed 1.00 1.00
Immediate 0.82 (0.64, 1.05) 0.85 (0.74, 0.98)*
HR.1 implies risk of second seizure is greater in alternative category than in the baseline category.
*Significant values (p,0.05).
doi:10.1371/journal.pone.0099063.t004
Table 5. Risk of seizure recurrence over 12 months at time points after first seizure: risk (%, 95% confidence interval) – unadjusted
estimates obtained from super-population comprising MESS, NGPSE, WA and FIRST.
Immediate Treatment Delayed Treatment
Time after first seizure
(months)
No. at risk
of seizure
Risk of seizure in
next 12 months (%)
No. at risk
of seizure
Risk of seizure in
next 12 months (%)
6 580 15 (12 to 18) 872 18 (15 to 21)
12 500 8 (6 to 11) 748 10 (8 to 13)
18 451 6 (4 to 9) 657 9 (7 to 11)
24 414 7 (4 to 9) 585 7 (5 to 9)
doi:10.1371/journal.pone.0099063.t005
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Figure 5. Risk of seizure recurrence in next 12 months estimated frommultivariable model at specific seizure-free periods. Estimates
presented assume seizures not confined to sleep and no first degree relative with epilepsy - MESS multivariable model fitted to super-population
comprising MESS, NGPSE, WA and FIRST. Imm= Immediate; Crypto,/Idio/ = Cryptogenic/Idiopathic; Symptomatic = Remote symptomatic. Risks are risk
of seizure in next 12 months with associated 95% confidence interval.
doi:10.1371/journal.pone.0099063.g005
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validation datasets are from a super-population. The three
external validation datasets investigated here were plausibly
related datasets to MESS but were not a perfect match. These
differences are, however, likely to have a minimal statistical impact
on the validity of using the non-matched data for external
validation purposes. This is because external validation focuses on
showing that a prognostic model or index, developed in one
dataset, also fits different data – if the data were too statistically
similar, the model may not be generalisable more widely.
Given that the model appears to be externally valid in
populations that are different in some respects to the MESS
dataset it may be possible to conclude that the model is more
useful as a clinical tool. The differences in populations may
actually be considered as an advantage too as they suggest that our
model is valid in a variety of settings.
Similarly, the model being externally validated is for use in the
UK. Two out of the three external validation datasets were,
however, not collected in the UK. Driving regulations in the EU,
and further afield, currently differ among member states but
minimum standards for driving are now in the process of being
implemented. In Australia a person may regain a driving license
following a first seizure provided they have been seizure free for at
least six months [23] which is in line with the UK [24] and EU
guidelines [25]. Therefore, by showing that our model is externally
valid in datasets from around the world, that differ in design and
included drugs for example, there is evidence to support one
overall prognostic model for risk of second seizure following a first.
This would ensure global harmonisation of driving regulations.
The choice of a 20% standard is arbitrary, although this
standard has been generally accepted across the EU during a
process of regulation harmonization. If the standard were
changed, data from these analyses could be extended to inform
regulators, clinicians and the public.
Conclusions
Our prognostic model has been validated, and extended to
include additional data to improve precision of estimates. The
model is a valuable tool for predicting risk of seizure recurrence
following a first seizure for people with various combinations of
risk factors. It can be used to inform driving regulation both within
the UK and across the world.
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